| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910456695803321 |
|
|
Autore |
Smith Peter F (Peter Frederick), <1930-, > |
|
|
Titolo |
Building for a changing climate : the challenge for construction, planning and energy / / Peter F. Smith |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
London ; ; Sterling, Va. : , : Earthscan, , 2010 |
|
|
|
|
|
|
|
ISBN |
|
1-136-54636-7 |
1-282-50600-5 |
9786612506000 |
1-84977-439-0 |
|
|
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (198 p.) |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
City planning - Environmental aspects |
Housing - Environmental aspects |
Climatic changes |
Sustainable urban development |
Electronic books. |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
Description based upon print version of record. |
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references (p. [171]-173) and index. |
|
|
|
|
|
|
Nota di contenuto |
|
1. Prepare for four degrees -- 2. Probable future impacts of climate change -- 3. The UN carbon trading mechanism -- 4. Setting the pace towards climate-proof housing -- 5. Future-proof housing -- 6. Building-integrated solar electricity -- 7. Sun, earth, wind and water -- 8. Eco-towns : opportunity or oxymoron? -- 9. The housing inheritance -- 10. On-domestic buildings -- 11. Community buildings -- 12. Conventional energy -- 13. Coal : black gold or black hole? -- 14. Filling the gap; utility-scale renewables -- 15. The age beyond oil -- 16. The thread of hope. |
|
|
|
|
|
|
|
|
Sommario/riassunto |
|
There is now a practically universal consensus that our climate is changing rapidly, and as a direct result of human activities. While there is extensive debate about what we can do to mitigate the damage we are causing, it is becoming increasingly clear that a large part of our resources will have to be directed towards adapting to new climatic conditions, with talk of survivability replacing sustainability as the new and most pressing priority. Nowhere is this more evident than in the |
|
|
|
|
|
|
|
|
|
|
|
|
|
built environment - the stage on which our most important interactions with climatic conditions ar |
|
|
|
|
|
|
2. |
Record Nr. |
UNINA9910502660103321 |
|
|
Autore |
Hays Priya <1968-> |
|
|
Titolo |
Advancing healthcare through personalized medicine / / Priya Hays |
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Cham, Switzerland : , : Springer, , [2022] |
|
©2022 |
|
|
|
|
|
|
|
|
|
ISBN |
|
|
|
|
|
|
Edizione |
[2nd ed.] |
|
|
|
|
|
Descrizione fisica |
|
1 online resource (755 pages) |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Precision medicine |
Medicina personalitzada |
Llibres electrònics |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Nota di contenuto |
|
Intro -- Preface to the Second Edition -- Acknowledgments -- Contents -- 1: "Introduction: Biomedical Innovation and Policy in the Twenty-First Century" -- Liquid Biopsy -- Challenges and Incentives for Implementation -- Components of the Book -- References -- 2: "The Rise of Genomics and Personalized Medicine" -- Human Genome Project, Sequencing, and Genomic Medicine -- New Innovative Studies in NGS -- Sanger Sequencing and Comparison with NGS -- Single-Cell RNA Sequencing -- Single-Cell Epigenetic Analysis -- Application of Single-Cell Analysis in Precision Cancer Therapy -- Genomic Medicine -- Genomic Sequencing for Assessment of Disease -- Potential Challenges of Genomic Medicine -- ENCODE: Mapping the Functional Genome -- Pharmacogenetics: Pharmacogenomics -- Thiopurine-Methyltransferase (TPMT) -- CYP2D6 -- CYP2C9 -- UDP-Glucoronyltransferase -- HIV and Abacavir -- Targeted Panel Sequencing -- Genomics-Enabled Medicine for Cancer Prognosis -- The Emergence of Personalized Medicine -- Biomarker Discovery -- Tumor Mutational Burden (TMB) as a Biomarker |
|
|
|
|
|
|
|
|
|
-- Germline Considerations -- Conclusion -- References -- 3: "Patient Narratives: Personalized Medicine in the Field" -- The Population of 1 Trial: The Story of Milasen -- The Narratives of Personalized Medicine -- Social Media's Avenues for Personalized Medicine -- Social Media for Patient Engagement -- Role of Twitter in Identifying Barriers to Care Among Patients with Metastatic Breast Cancer [6] -- The Narrative of Xin Zheng: A Lung Cancer Success Story -- References -- 4: Alliances: Knowledge Infrastructures, and the Digitization of Precision Health -- Precision Medicine: Its Potential Development and Implementation -- Implications of Precision Medicine for Patient Care and Disease Treatment -- Monitoring the Personal Genome -- Macroeconomic Considerations of Precision Medicine. |
Global Alliance for Genomics and Health -- Updates to Global Alliance for Genomics and Health: GA4GH 2020 (Figs. 4.7, 4.8, 4.9, and 4.10) -- Systems Thinking and -Omics Technologies -- Data Portals and Data Analysis -- Bridging the Gap for Translational Genomic Research -- Database Efforts -- Genomics and Artificial Intelligence -- Deep Learning Methods in Precision Medicine -- Digital Precision Health: The History of Machine Learning and the Power of Big Data for Clinical Medicine -- Digital Pathology -- Conclusion -- References -- 5: "Great Strides in Precision Medicine: Personalized Oncology, Immunotherapies, and Molecular Diagnostics" -- An Immunotherapy Case Report -- A Target Therapy Case Report -- The Basis for Targeted Therapies: Acquired Mutations and Biomarkers in Cancers -- Oncogenesis -- Implications of Tumor Heterogeneity -- Enrichment and Adaptive Strategies -- Molecular Abnormalities in Solid Tumors -- Germline Molecular Testing for Hereditary Cancer Risk -- Cell Cycle Checkpoints -- Understanding Clinical Trials in the Era of Precision Oncology: Data, Biomarkers, and Diagnostic Testing -- Analysis -- Action -- N of 1 Trial -- Tumor Subtypes -- Breast Cancer -- Incidence and Mortality -- Inherited Breast Cancer -- Targeted Therapy Options in Breast Cancer Care -- Tyrosine Kinase Inhibitor: Tucatinib -- HER2+ /HER2-Positive Breast Cancer -- Triple-Negative Breast Cancer (TNBC) and Metastatic Breast Cancer (mBC) -- Biomarker Predicting Response to PARP Inhibitors -- "Study Supports Using MRD as a Stratification Variable for Patients with TNBC" -- "Unexpected Survival Benefit Reported With Trilaciclib in Metastatic Triple-Negative Breast Cancer" -- Olaparib -- Talazoparib -- Immunotherapy and Immunotherapy Combinations -- Newer Generation Targeted Therapy Agents -- Abemaciclib -- Other Combination Agents -- Recent Immunotherapies. |
Tecentriq -- Pembrolizumab -- Avelumab -- Liquid Biopsy in Breast Cancer: A Systematic Review -- Current Breast Cancer Diagnosis Standards -- Oncotype DX -- MammaPrint -- PAM50 (Prosigna) -- Genomic Grade Index (GGI) (Ipsogen) -- Veridex Rotterdam Signature 76 Genes -- Ventana HER2 Dual ISH DNA Probe Cocktail Assay for Detection of HER2 -- RSClin TOOL: 21-Gene Recurrence Score (RS) -- HER2DX -- Signatera MRD Test -- Findings for Protein-Truncating and Missense Variants -- "Study Suggests 86-SNV Be Incorporated in Breast Cancer Risk Prediction Models" -- Conclusion -- Colorectal Cancer -- Incidence and Mortality -- Colorectal Cancer Classification Systems -- Molecular Pathology and Diagnosis of Colorectal Cancer -- "Molecular Testing in Metastatic Colorectal Cancer: Understanding How, When, and What to Profile" -- Inherited CRC Syndrome -- Hereditary Nonpolyposis Colorectal Carcinoma (Lynch Syndrome) -- Familial Adenomatous Polyposis -- De Novo Colorectal Cancer -- BRAF V600E -- Additional CRC Biomarkers and Mutations -- Targeted and Immunotherapies -- Bevacizumab -- Cetuximab -- Panitumumab -- Ramucirumab -- Ziv-aflibercept -- ASPECCT Trial [76] -- |
|
|
|
|
|
|
|
Immunotherapies for CRC: A Recent Development -- Immunotherapy for the Nonimmunogenic Tumors -- Liquid Biopsy -- Conclusion -- Melanoma -- Incidence and Mortality -- Targeted Therapies -- BRAF-V600E Inhibitors -- Immunotherapies for Melanoma -- Multicenter Double-Blind Phase III IMMUNED Trial -- The Phase III Double-Blind EORTC 1325/KEYNOTE-054 Trial (continued) -- Immunotherapies in Combination with Targeted Agents -- Adoptive Cell Therapy for Metastatic Melanoma -- Liquid Biopsy -- "Pretreatment ctDNA May Help Predict Outcomes With First-Line-but Not Second-Line-Immunotherapy for Patients With Melanoma" -- Management of Brain Metastases from cuM -- Conclusion -- Lung Cancer -- Incidence and Mortality. |
Targeted Therapies -- "Pyrotinib for Pretreated Patients with HER2-Mutated Advanced NSCLC" -- Erlotinib -- Gefitinib -- Afatinib -- Capmatinib -- Dacomitinib -- Summary of Erlotinib, Gefitinib, and Afatinib -- Sotorasib -- Ceritinib -- Alectinib -- Brigatinib -- Lorlatinib -- Selpercatinib -- Pralsetinib -- Newer Targeted Therapy Agents -- Osimertinib -- Tepotinib -- Use of Liquid Biopsy in the Trial -- Poziotinib -- Ramucirumab/Erlotinib -- Mobocertinib -- Capmatinib -- Brigatinib -- Adagrasib -- Immunotherapies -- Addition of Nivolumab to Neoadjuvant Chemotherapy in Resectable Stage IIIA NSCLC -- KEYNOTE-024 -- KEYNOTE-042 -- KEYNOTE-189 -- KEYNOTE-407 -- KEYNOTE Trials Adverse Events -- IMpower Trials -- IMpower 110 -- IMpower 130 -- IMpower 131 -- IMpower 150 -- Durvalumab -- Comparative Analysis of Pembrolizumab or Nivolumab in NSCLC -- The ORIENT-11 Trial Showed Sintilimab Plus Chemotherapy Improves PFS in Advanced NSCLC -- The PD-L1 Status Dilemma -- CheckMate Trials -- CheckMate 227 -- CheckMate 9LA -- Molecular Diagnosis -- Molecular Genotyping in NSCLC -- Role of Plasma-Based Molecular Genotyping in NSCLC -- Liquid Biopsy -- Case Studies of Liquid Biopsy in Lung Cancer -- Case Study 1 -- Case Study 2 -- Case Study 3 -- Case Studies 4 and 5 -- Case Study 6 -- Conclusion -- Prostate Cancer -- Incidence and Mortality -- Genomic Medicine and Sequencing -- Newer Generation Targeted Therapies -- Prostate-Specific Membrane Antigen -- PARP Inhibitors -- "Pan-BET Bromodomain Inhibitor Plus Enzalutamide in Advanced Prostate Cancer" -- Rucaparib -- Non-metastatic Prostate Cancer -- PROSPER -- SPARTAN -- ARAMIS -- Summary of PROSPER, SPARTAN, and ARAMIS -- Immunotherapies -- Molecular Diagnosis -- Liquid Biopsy -- Genetic Screening -- Which Men Should Be Evaluated for Prostate Cancer?. |
Key Genomic Differences Identified in the Prostate Cancer of African-American Men -- "Series of Studies Identify Genetic Risk Factors for Prostate Cancer" -- "17q22 Loss Associated With Survival in Enzalutamide-Resistant mCRPC" -- Racial Differences in Genomic Profiles of Primary and Metastatic Prostate Cancer -- "Study Finds Differences in BRCA1/2 Male Pathogenic Variant Carriers" -- Diagnostic Tests -- 4 k Score -- Prostate Health Index (PHI) -- Prostate Cancer Antigen 3 Assay (PCA3) -- SelectMDx -- ExoDx Prostate Intelliscore (EPI) -- ConfirmMDx -- Prognostic Tests -- Decipher (GC) -- Post-operative Radiation Therapy Outcomes Score -- Promark -- Prolaris -- OncotypeDx Genomic Prostate Score (GPS) -- Precision Imaging -- Conclusion -- Central Nervous System Tumors -- Incidence and Mortality -- Molecular Classification of Glioblastoma -- Diffuse Astrocytic and Oligodendroglial Tumors -- IDH-Mutated Astrocytomas -- Biomarkers and Targeted Therapies -- Tumor Immunology -- Subset of Glioblastoma Tumors Identified as Immunotherapy Candidate -- Meningiomas -- Hemangioblastomas -- Conclusion -- |
|
|
|
|
|
|
|
|
Hematological Malignancies -- Incidence and Mortality -- Hematologic Oncology Highlights 2019-2020 Almanac -- Chronic Myeloid Leukemia and Acute Lymphocytic Leukemia -- Study Finds Asciminib Safer and More Effective than TKI Bosutinib in Chronic Phase CML -- "Effects of Stopping Tyrosine Kinase Inhibitor Treatment for Chronic Myeloid Leukemia: -- Focus on Molecular Response and Patient-Reported Outcomes" -- "First-Line Dasatinib Plus Blinatumomab for Adult Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia" -- Clinical Trials Investigating the Efficacy and Safety of the Novel CART Therapies UCART 19 and UCART22 in R/R B-Cell ALL -- "Chemotherapy Plus Blinatumomab for Philadelphia Chromosome-Negative B-Cell ALL". |
"FDA Grants Fast Track Designation to Allogeneic CAR T-Cell Therapy for Advanced ALL". |
|
|
|
|
|
| |